Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Details

Instance of

clinical trial

Start time

November 2012

End time

December 2013

Country

Japan

Main subject

thyroid medullary carcinoma, carcinoma

clinical trial phase

phase I clinical trial, phase II clinical trial

minimum age

20

number of participants

14

study type

interventional study

title

A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma